Hydrogen sulfide in hypertension

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 2, 2016, Pages 107-113

  Van Goor, Harry ^a   Van Den Born, Joost C ^a   Hillebrands, Jan Luuk ^a   Joles, Jaap A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

blood pressure; hydrogen sulfide; hypertension; thiosulfate

Indexed keywords

3 MERCAPTOPYRUVATE SULFURTRANSFERASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYSTATHIONINE GAMMA LYASE; DRUG METABOLITE; HYDROGEN SULFIDE; REACTIVE OXYGEN METABOLITE; THIOSULFATE; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CALCINOSIS; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FREE RADICAL SCAVENGING ASSAY; HUMAN; HYPERTENSION; INTERVENTION STUDY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYDROGEN SULFIDE; HYPERTENSION; THIOSULFATES;

EID: 84957429051     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000206     Document Type: Review

References (62)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260.
2. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104:503-516.
3. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-2116.
4. Shen X, Carlstrom M, Borniquel S, et al. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med 2013; 60:195-200.
5. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 2015; 24:403-409.
6. Nagy P, Palinkas Z, Nagy A, et al. Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim Biophys Acta 2014; 1840:876-891.
7. Kabil O, Banerjee R. Enzymology of H2S biogenesis, decay and signaling. Antioxid Redox Signal 2014; 20:770-782.
8. Van den Berg E, Pasch A, Westendorp WH, et al. Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients. J Am Soc Nephrol 2014; 25:1303-1312.
9. Cortese-Krott MM, Kuhnle GG, Dyson A, et al. Key bioactive reaction products of the NO/H2S interaction are S/N-hybrid species, polysulfides, and nitroxyl. Proc Natl Acad Sci USA 2015; 112:E4651-E4660.
10. Roy A, Khan AH, Islam MT, et al. Interdependency of cystathione gamma-lyase and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J Hypertens 2012; 25:74-81.
11. Wesseling S, Fledderus JO, Verhaar MC, Joles JA. Beneficial effects of diminished production of hydrogen sulfide or carbon monoxide on hypertension and renal injury induced by NO withdrawal. Br J Pharmacol 2015; 172:1607-1619.
12. Duan XC, Guo R, Liu SY, et al. Gene transfer of cystathionine beta-synthase into RVLM increases hydrogen sulfide-mediated suppression of sympathetic outflow via KATP channel in normotensive rats. Am J Physiol Heart Circ Physiol 2015; 308:H603-H611.
13. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587-590.
14. Ishii I, Akahoshi N, Yamada H, et al. Cystathionine gamma-Lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J Biol Chem 2010; 285:26358-26368.
15. Cheung SH, Kwok WK, To KF, Lau JY. Antiatherogenic effect of hydrogen sulfide by over-expression of cystathionine gamma-lyase (CSE) gene. PLoS One 2014; 9:e113038.
16. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 1997; 237:527-531.
17. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 2001; 20:6008-6016.
18. Mustafa AK, Sikka G, Gazi SK, et al. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 2011; 109:1259-1268.
19. Eberhardt M, Dux M, Namer B, et al. H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nat Commun 2014; 5:4381.
20. Burgoyne JR, Madhani M, Cuello F, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007; 317:1393-1397.
21. Prysyazhna O, Rudyk O, Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med 2012; 18:286-290.
22. Stubbert D, Prysyazhna O, Rudyk O, et al. Protein kinase G α oxidation paradoxically underlies blood pressure lowering by the reductant hydrogen sulfide. Hypertension 2014; 64:1344-1351.
23. Fusco F, di Villa Bianca R, Mitidieri E, et al. Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol 2012; 62:1174-1180.
24. d'Emmanuele di Villa Bianca R, Sorrentino R, Mirone V, Cirino G. Hydrogen sulfide and erectile function: a novel therapeutic target. Nat Rev Urol 2011; 8:286-289.
25. Whiteman M, Gooding KM, Whatmore JL, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 2010; 53:1722-1726.
26. Ahmad FU, Sattar MA, Rathore HA, et al. Hydrogen sulphide and tempol treatments improve the blood pressure and renal excretory responses in spontaneously hypertensive rats. Ren Fail 2014; 36:598-605.
27. Sun L, Jin H, Sun L, et al. Hydrogen sulfide alleviates myocardial collagen remodeling in association with inhibition of TGF-beta/Smad signaling pathway in spontaneously hypertensive rats. Mol Med 2015; 20:503-515.
28. Zhao X, Zhang LK, Zhang CY, et al. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res 2008; 31:1619-1630.
29. Sikora M, Drapala A, Ufnal M. Exogenous hydrogen sulfide causes different hemodynamic effects in normotensive and hypertensive rats via neurogenic mechanisms. Pharmacol Rep 2014; 66:751-758.
30. Huang P, Chen S, Wang Y, et al. Down-regulated CBS/H2S pathway is involved in high-salt-induced hypertension in Dahl rats. Nitric Oxide 2015; 46:192-203.
31. Al-Magableh MR, Kemp-Harper BK, Hart JL. Hydrogen sulfide treatment reduces blood pressure and oxidative stress in angiotensin II-induced hypertensive mice. Hypertens Res 2015; 38:13-20.
32. Snijder PM, Frenay AR, Koning AM, et al. Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renal damage. Nitric Oxide 2014; 42:87-98.
33. Oosterhuis NR, Frenay AR, Wesseling S, et al. dl-propargylglycine reduces blood pressure and renal injury but increases kidney weight in angiotensin-II infused rats. Nitric Oxide 2015; 49:56-66.
34. Zhong G, Chen F, Cheng Y, et al. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J Hypertens 2003; 21:1879-1885.
35. Ji W, Liu S, Dai J, et al. Hydrogen sulfide defends against the cardiovascular risk of Nw-nitro-L-argininemethyl ester-induced hypertension in rats via the nitric oxide/endothelial nitric oxide synthase pathway. Chin Med J (Engl) 2014; 127:3751-3757.
36. Sharma DK, Manral A, Saini V, et al. Novel diallyldisulfide analogs ameliorate cardiovascular remodeling in rats with L-NAME-induced hypertension. Eur J Pharmacol 2012; 691:198-208.
37. Yang G, Li H, Tang G, et al. Increased neointimal formation in cystathionine gamma-lyase deficient mice: role of hydrogen sulfide in alpha5beta1-integrin and matrix metalloproteinase-2 expression in smooth muscle cells. J Mol Cell Cardiol 2012; 52:677-688.
38. Snijder PM, Frenay AS, de Boer RA, et al. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats. Br J Pharmacol 2014; 172:1494-1504.
39. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17:629-634.
40. Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann Emerg Med 2007; 49:806-813.
41. Peh MT, Anwar AB, Ng DS, et al. Effect of feeding a high fat diet on hydrogen sulfide (H2S) metabolism in the mouse. Nitric Oxide 2014; 41:138-145.
42. Meng QH, Yang G, Yang W, et al. Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries. Am J Pathol 2007; 170:1406-1414.
43. Wang Y, Zhao X, Jin H, et al. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2009; 29:173-179.
44. Calvert JW, Jha S, Gundewar S, et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 2009; 105:365-374.
45. Snijder PM, de Boer RA, Bos EM, et al. Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolism. PLoS One 2013; 8:e63291.
46. Wei X, Zhang B, Cheng L, et al. Hydrogen sulfide induces neuroprotection against experimental stroke in rats by down-regulation of AQP4 via activating PKC. Brain Res 2015; 1622:292-299.
47. Geng B, Cai B, Liao F, et al. Increase or decrease hydrogen sulfide exert opposite lipolysis, but reduce global insulin resistance in high fatty diet induced obese mice. PLoS One 2013; 8:e73892.
48. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J 2011; 162:959-965.
49. Romero MJ, Platt DH, Caldwell RB, Caldwell RW. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006; 24:275-290.
50. Park J, Liao P, Sher S, et al. Tetrahydrobiopterin lowers muscle sympathetic nerve activity and improves augmentation index in patients with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2015; 308:R208-R218.
51. Toombs CF, Insko MA, Wintner EA, et al. Detection of exhaled hydrogen sulphide gas in healthy human volunteers during intravenous administration of sodium sulphide. Br J Clin Pharmacol 2010; 69:626-636.
52. Libiad M, Yadav PK, Vitvitsky V, et al. Organization of the human mitochondrial hydrogen sulfide oxidation pathway. J Biol Chem 2014; 289:30901-30910.
53. Mishanina TV, Libiad M, Banerjee R. Biogenesis of reactive sulfur species for signaling by hydrogen sulfide oxidation pathways. Nat Chem Biol 2015; 11:457-464.
54. Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 2013; 8:1162-1170.
55. Pasch A, Schaffner T, Huynh-Do U, et al. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 2008; 74:1444-1453.
56. Bijarnia RK, Bachtler M, Chandak PG, et al. Sodium thiosulfate ameliorates oxidative stress and preserves renal function in hyperoxaluric rats. PLoS One 2015; 10:e0124881.
57. Bhatia M, Sidhapuriwala JN, Sparatore A, Moore PK. Treatment with H2Sreleasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock 2008; 29:84-88.
58. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010; 159:1236-1246.
59. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007; 6:917-935.
60. Kashfi K, Olson KR. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol 2013; 85:689-703.
61. Buikema H, Monnink SH, Tio RA, et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130:1999-2007.
62. Bucci M, Vellecco V, Cantalupo A, et al. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc Res 2014; 102:138-147.